Profound Medical Corp. (PROF): Price and Financial Metrics
PROF Price/Volume Stats
| Current price | $10.40 | 52-week high | $15.49 |
| Prev. close | $10.21 | 52-week low | $4.50 |
| Day low | $10.06 | Volume | 39,000 |
| Day high | $10.40 | Avg. volume | 24,553 |
| 50-day MA | $9.55 | Dividend yield | N/A |
| 200-day MA | $10.94 | Market Cap | 222.21M |
PROF Stock Price Chart Interactive Chart >
Profound Medical Corp. (PROF) Company Bio
Profound Medical Corp. operates as a medical device company. The Company develops and commercializes technology for the treatment of localized prostate cancer. Profound Medical offers its services worldwide.
Latest PROF News From Around the Web
Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Profound Medical to Participate in the Stifel 2023 Healthcare ConferenceTORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. Eastern Time in NYC. The presentation will be broadcast live and archi |
Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC SettingTORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, pursuant to the 2024 Final Rule published yesterday by the U.S. Centers for Medicare and Medicaid Services (“CMS”), use of HCPCS C code, C9734, previously established for the Hospital Outpatient Prospective Payment |
Profound Medical Announces Third Quarter 2023 Financial ResultsTORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Rep |
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to FollowTORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2023 financial results after market close on Thursday, November 2, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in |
Profound Medical 2023 Virtual Analyst & Investor Day AgendaTORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its Analyst & Investor Day event scheduled for Friday, October 13, 2023. The agenda will commence at 1:00 p.m. and is scheduled to conclude at approximately 3:30 p.m. Eastern Time. The program |
PROF Price Returns
| 1-mo | 25.15% |
| 3-mo | 15.04% |
| 6-mo | -22.33% |
| 1-year | 118.49% |
| 3-year | -47.84% |
| 5-year | N/A |
| YTD | -4.50% |
| 2022 | -3.03% |
| 2021 | -45.38% |
| 2020 | 87.76% |
| 2019 | 160.71% |
| 2018 | -35.64% |
Loading social stream, please wait...